title: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).
abstract: Vascular endothelial growth factor (VEGF) was originally identified as an endothelial cell specific growth factor stimulating angiogenesis and vascular permeability. Some family members, VEGF C and D, are specifically involved in lymphangiogenesis. It now appears that VEGF also has autocrine functions acting as a survival factor for tumour cells protecting them from stresses such as hypoxia, chemotherapy and radiotherapy. The mechanisms of action of VEGF are still being investigated with emerging insights into overlapping pathways and cross-talk between other receptors such as the neuropilins which were not previously associated with angiogenesis. VEGF plays an important role in embryonic development and angiogenesis during wound healing and menstrual cycle in the healthy adult. VEGF is also important in a number of both malignant and non-malignant pathologies. As it plays a limited role in normal human physiology, VEGF is an attractive therapeutic target in diseases where VEGF plays a key role. It was originally thought that in pathological conditions such as cancer, VEGF functioned solely as an angiogenic factor, stimulating new vessel formation and increasing vascular permeability. It has since emerged it plays a multifunctional role where it can also have autocrine pro-survival effects and contribute to tumour cell chemoresistance. In this review we discuss the established role of VEGF in angiogenesis and the underlying mechanisms. We discuss its role as a survival factor and mechanisms whereby angiogenesis inhibition improves efficacy of chemotherapy regimes. Finally, we discuss the therapeutic implications of targeting angiogenesis and VEGF receptors, particularly in cancer therapy.
authors.affiliation: Royal College of Surgeons in Ireland, Department of Surgery, Education and Research Centre, Beaumont Hospital, Dublin.
authors.forename: Anne Marie
authors.initials: AM
authors.lastname: Byrne
authors.forename: D J
authors.initials: DJ
authors.lastname: Bouchier-Hayes
authors.forename: J H
authors.initials: JH
authors.lastname: Harmey
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001172:Arthritis, Rheumatoid / Q000378:metabolism; D002465:Cell Movement; D049109:Cell Proliferation; D002470:Cell Survival; D003920:Diabetes Mellitus / Q000378:metabolism; D005091:Exons; D005786:Gene Expression Regulation; D006801:Humans; D000860:Hypoxia; D008024:Ligands; D008954:Models, Biological; D009369:Neoplasms / Q000378:metabolism; D009389:Neovascularization, Pathologic; D018919:Neovascularization, Physiologic; D011485:Protein Binding; D020033:Protein Isoforms; D011565:Psoriasis / Q000378:metabolism; D012098:Reproduction; D015398:Signal Transduction; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism / Q000502:physiology*; D014945:Wound Healing
chemical_list: D000970:Antineoplastic Agents; D008024:Ligands; D020033:Protein Isoforms; D042461:Vascular Endothelial Growth Factor A